Au cours de cette étude, nous avons approfondi nos connaissances concernant l’effet des conditions de culture sur la quantité et la qualité d’une protéine recombinante produite par des cellules CHO. En particulier, nous avons étudié l’influence de 3 composés (citrate de fer, pluronic F-68 et éthanolamine) présents dans le milieu BDM mais absent du milieu RPMI avec sérum (FCS-RPMI) sur la croissance des cellules CHO, la production de l’interféron-gamma humain recombinant (IFN-γ) ainsi que sa qualité. L’ajout de pluronic F-68 (0,1%) et de citrate de fer (500 µM) dans le milieu RPMI sans sérum a permis d’obtenir une croissance cellulaire comparable à celle obtenue avec le milieu FCS-RPMI. Par ailleurs, dans ces conditions de culture, la production de l’IFN-g est également augmentée. L’ajout de citrate de fer dans le milieu FCS-RPMI permet non seulement d’améliorer la croissance des cellules CHO mais également la production de l’IFN-γ. Avec le milieu FCS-RPMI, la macrohétérogénéité de la glycosylation de l’IFN-γ change au cours du procédé discontinu, cette dernière est maintenue constante uniquement lorsque du citrate de fer est ajouté à ce même milieu de culture. En outre, des activités gélatinase et caséinase appartenant aux familles des métalloprotéases et des protéases à sérine ont été mises en évidence au cours des cultures de cellules CHO. Quel que soit le milieu utilisé (RPMI, BDM avec ou sans sérum), l’ajout de citrate de fer permet de maîtriser et d’éviter la protéolyse de l’IFN-γ. Enfin, la relation entre le degré de glycosylation macroscopique de l’IFN- γ et son activité biologique (immunomodulatrice) in-vitro a été établie / In this study, we characterized the effect of culture conditions on the quantity and the quality of a recombinant protein, IFN-γ, produced by CHO cells. In particular, we studied the effect of 3 components (iron citrate, pluronic F-68 and ethanolamine) that are present in the BDM medium, but completely lacking in RPMI serum medium (FCS-RPMI) on CHO cell growth, as well as the production and quality of recombinant IFN-γ.The addition of Pluronic F-68 (0.1%) and iron citrate (500 µM) in RPMI without serum resulted in growth kinetic performances similar to those observed in FCS-RPMI. Furthermore, in these culture conditions, IFN- γ production was improved. Addition of iron citrate in FCS-RPMI improved cell growth, as well as IFN-γ production. Whereas the glycosylation pattern of recombinant IFN-γ produced by CHO cells was not constant when the culture was performed in FCS-RPMI, the glycosylation pattern of IFN-γ remained constant when iron citrate was added in the medium. In addition, gelatinase and caseinase enzymatic activities in CHO batch cultures were detected, due most likely to enzymes of the metalloproteases and serine protease families. Despite the type of medium used (RPMI, BDM with or without serum), addition of iron citrate minimized IFN-g proteolysis. Finally, the relationship between the macroglycosylation pattern of IFN-g and its in-vitro biological (immunomodulatory) activity was demonstrated

O objetivo do projeto foi desenvolver linhagens celulares para um anticorpo terapêutico anti-hTNFα e comprovar sua funcionalidade. Os genes anti-hTNFα foram clonados em células CHO para seleção da população estável mista, demonstrando expressão de anticorpo com reconhecimento de hTNFα em estrutura tridimensional. A população de transfectantes de maior produtividade específica foi escolhida para geração de linhagem monoclonal utilizando a tecnologia robótica ClonePix FL. Não houve diferença estatística entre o anti-hTNFα purificado e o produto de referência na cinética de ligação ao TNFα e reconhecimento diferencial por FcγRs em ensaios por SPR O ensaio de atividade funcional mostrou que o anti-TNFα desenvolvido pôde neutralizar a citotoxicidade induzida em células L929 e inibir a expressão de ELAM-1 em HUVEC. Os resultados finais permitiram identificar os três melhores clones, estáveis por 60 gerações. A comparabilidade entre o anti-TNFα desenvolvido e a referência permite admiti-lo como não inferior, um dos requisitos para o desenvolvimento de biossimilar. / The aim of the project was to develop a therapeutic anti-hTNFα antibody and evaluate its functionality. The anti-hTNFα synthezised genes were cloned into CHO cells and stable pools were selected, producing antibodies able to hTNFα three-dimensional structure recognition. The stable pools displaying higher antibody yields were the source for the generation of monoclonal lineage by ClonePix FL robotic technology. The clones selection proceeded using different criteria as cell density, specific productivity, fed-batch performance, kinetics measured by surface plasmonic resonance, hTNFα binding through ELISA, western-blotting and SPR, FcγRs binding by SPR. Besides, a small number of clones was tested in functional assays by the impairment of cytotoxicity of hTNFα over L929 cells and the inhibition of ELAM-1 expression by HUVEC. The long term stability testing allowed to finally select 3 top clones, not inferior to adalimumab reference by the above criteria.

A produção de proteínas recombinantes, principalmente para uso farmacêutico, tem sido intensamente estudada, juntamente com suas propriedades físico-químicas, o que possibilita uma melhor escolha da técnica de purificação, e assim, evitar perdas no rendimento e custos elevados. A glicocerebrosidase (GCR) é uma enzima lisossomal, e sua deficiência ocasiona um distúrbio autossômico recessivo denominado doença de Gaucher. Atualmente o tratamento para essa patologia é por meio da Terapia de Reposição Enzimática (TRE), a qual tem sido realizada com grande êxito. Tendo em vista fornecer dados que possam auxiliar na redução do número de etapas cromatográficas no processo de downstream, este trabalho teve como objetivo, a purificação da GCR expressa por células de Ovário de Hamster Chinês (CHO), em meio livre de soro fetal bovino (SFB). Para se alcançar tais resultados, realizou-se o cultivo das células CHO-GCR em meio quimicamente definido livre de SFB (CHO-S-SFM II). Foram realizadas três técnicas cromatográficas (troca iônica, interação hidrofóbica e afinidade), com base em suas propriedades físico-químicas. E para o ensaio da atividade enzimática, foi utilizado o substrato fluorogênico 4-Methylumbeliferyl β-D-glucopyranoside (4MU-G). As células CHO-GCR cultivadas em meio CHO-S-SFM II, apresentando viabilidade maior que 95%, e produção da GCR ativa, durante todo o período de cultivo. Os protocolos aplicados para a purificação da GCR, não apresentaram resultados significativos. Com o volume não retido após cromatografia por interação hidrofóbica, se estimou os valores de KM 2,13 e VMAX 0,0295 UFR/h para as constantes cinéticas da GCR. A diálise no processo de purificação mostrou ser uma etapa necessária para a atividade enzimática da GCR. No cultivo das células CHO-GCR para a formação do banco de trabalho, nos meios RPMI 1640 e α-MEM, ambos com a adição de 10% SFB, não houve diferença significativa no crescimento entre eles, e apresentaram 100% de viabilidade durante todo o período de cultivo. Porém, ao analisar de forma isolada a fase exponencial de cada curva, notou-se que às células cultivadas no meio RPMI 1640, apresentaram taxa de crescimento superior, às cultivadas em meio α-MEM. Concluiu-se que a expressão da GCR em meio livre de SFB, proporciona amostras menos complexas, em relação aos meios de cultura que necessitam de suplementação com SFB, o que pode reduzir o número de etapas cromatográficas, melhorando o rendimento e a redução da perda da atividade da GCR. O meio basal RPMI 1640 com a adição de SFB foi uma alternativa satisfatória para o cultivo das células CHO-GCR. Este estudo forneceu dados que podem contribuir para a melhoria do processo de purificação da GCR. Novas pesquisas podem ser desenvolvidas a fim de melhorar o processo de purificação da GCR. / The production of recombinant proteins, mainly for pharmaceutical use, has been intensively studied along with its physico-chemical properties, which allows a better choice of the purification technique, and thus avoid losses in yield and high costs. Glucocerebrosidase (GCR) is a lysosomal enzyme, and its deficiency causes an autosomal recessive disorder called Gaucher\'s disease. Currently the treatment for this pathology is through Enzymatic Replacement Therapy (ERT), which has been successfully performed. In order to provide data that may help reducing the number of chromatographic steps in the downstream process, this work aimed to purify GCR expressed by Chinese Hamster Ovary (CHO) cells in fetal bovine serum free (FBS). To achieve such results, the CHO-GCR cells were cultured in chemically defined Serum-free medium (CHO-S-SFM II). Three chromatographic techniques (ion exchange, hydrophobic interaction and affinity) were performed, based on their physicochemical properties. And for the enzymatic activity assay, the fluorogenic substrate 4-Methylumbeliferyl β-D-glucopyranoside (4MU-G) was used. CHO-GCR cells cultured in CHO-S-SFM II medium, presenting viability greater than 95% and GCR production active, throughout the culture period. The protocols applied for GCR purification did not present significant results. With the volume not retained after chromatography by hydrophobic interaction, KM values of 2.13 and VMAX 0.0295 UFR/h were estimated for GCR kinetic constants. Dialysis in the purification process was shown to be a step necessary for the enzymatic activity of GCR. In the culture of the CHO-GCR cells for the formation of the working bank, in the media RPMI 1640 and α-MEM, both with the addition of 10% FBS, there was no significant growth difference between them, and they showed 100% viability during all the growing period. However, when analyzing in isolation, the exponential phase of each curve, it was observed that the cells grown in RPMI 1640 medium showed higher growth rates, tham grown in α-MEM medium. It was concluded that the expression of GCR in serum-free medium provides less complex samples, relative to the culture media requiring FBS supplementation, which may reduce the number of chromatographic steps, improving yield and loss reduction of GCR activity. The basal medium RPMI 1640 with the addition of FBS was a satisfactory alternative for culturing the CHO-GCR cells. This study provided data that may contribute to the improvement of the GCR purification process. New research can be developed to improve the GCR purification process.

Uma linhagem celular de CHO, previamente modificada geneticamente pela introdução de cDNA da 2,6 sialiltransferase de rato, gerou, pela primeira vez, um hTSH recombinante com sialilação humanizada (hlsr-hTSH), mais similar ao hormônio nativo, com 61% de ligação de ácido siálico na conformação 2,3 e 39%, na conformação 2,6. O clone mais produtivo, quando submetido à amplificação gênica com 8 M de metotrexato, apresentou um nível de secreção de aproximadamente 2 g de hTSH/106 células/dia, nível este útil para a purificação e caracterização do produto. A massa molecular relativa do heterodímero e das subunidades e do hlsr-hTSH purificado, determinada por espectrometria de massa MALDI-TOF, e a hidrofobicidade relativa, determinada por RP-HPLC, não apresentaram diferenças significativas com relação às preparações de hTSH recombinante derivadas de células CHO sem a modificação devida ao gene da 2,6 sialiltransferase. Entretanto, algumas diferenças foram observadas na composição dos N-glicanos, com mais estruturas tri- e tetra-sialiladas no hlsr-hTSH. O hlsr-hTSH mostrou-se eqüipotente (p>0,05) à preparação comercial de r-hTSH (Thyrogen) e 1,5 vezes mais potente do que a preparação nativa de hTSH (p<0,001), quando analisado por um bioensaio in vivo baseado na capacidade do TSH de estimular a liberação de T4. / A CHO cell line, previously genetically modified by the introduction of rat 2,6-sialyltransferase cDNA, generated for the first time a human-like sialylated recombinant hTSH (hlsr-hTSH) more similar to the native hormone, with 61% of 2,3- and 39% of 2,6-linked sialic acid residues. The best clone, when submitted to gene amplification with up to 8 M methotrexate, presented a secretion level of ~2 g hTSH/106 cells/day, useful for product purification and characterization. The relative molecular masses (Mr) of the heterodimer and of the - and -subunits of purified hlsr-hTSH, determined by MALDI-TOF mass spectrometry, and the relative hydrophobicities, determined by RP-HPLC, were not remarkably different from those presented by two r-hTSH preparations secreted by normal CHO cells. Some differences were observed, though, in N-glycan composition, with more tri- and much more tetra-sialylated structures in hlsr-hTSH. When analyzed via an in vivo bioassay based on hTSH-induced T4 release in mice, hlsr-hTSH was shown to be equipotent (p > 0.05) with the commercial preparation of r-hTSH (Thyrogen), and 1.5-fold more potent than native hTSH (p < 0.001).

No description available.

Les anticorps monoclonaux sont une classe de bio médicaments en plein essor. Leur production est largement étudiée afin d’obtenir des rendements de plus en plus élevés et de réduire les coûts. Cette thèse décrit le développement d’un procédé complet en continu, de la production d’anticorps recombinants par des cellules mammifères jusqu’à leur purification. L’objectif est de coupler la culture cellulaire en mode perfusion à la purification par chromatographie semi-continue. Le développement du procédé se fait en bioréacteur avec une lignée de cellules d’ovaires de hamster chinois (CHO-DP12) transformée pour produire un anticorps anti-Interleukine 8 utilisée, comme modèle. Après adaptation, les cellules ont été cultivées en mode batch afin de connaitre le comportement de la lignée en environnement contrôlé. Ensuite, un procédé de perfusion de 2L de culture avec recyclage cellulaire a été mis en place. Le principal enjeu est de maintenir un état stationnaire avec une concentration cellulaire constante et déterminer le débit optimal d’alimentation spécifique par cellule (CSPR). Plusieurs méthodes ont été testées et comparées pour la détermination de ce CSPR optimal. Le procédé de culture en perfusion a ensuite été maintenu pendant 24 jours à des concentrations cellulaires de 10, 20 et 40 millions de cellules par mililitres. Les anticorps produit par différents modes de culture ont été caractérisés (batch, fed-batch et perfusion). Les N-glycosylations, les variants de charge ainsi que la thermo-stabilité des anticorps ont été étudiés. Les résultats montrent que les anticorps produits présentent des caractéristiques similaires quel que soit le mode de production.Pour la purification, une étude préliminaire a permis de caractériser le comportement du filtrat sur la résine chromatographique d’affinité MabSelect Sure LX en chromatographie classique. Un procédé semi-continu a été simulé grâce au logiciel BioSC® Predict puis testé et optimisé sur le chromatographe BioSC®. Il comprend la purification de l’anticorps mais aussi les étapes de nettoyages et de sanitisation. Un premier essai de couplage production/purification a pu être réalisé avec succès pendant 32h et a permis d’obtenir un niveau de pureté similaire à la chromatographie classique. La productivité a été augmentée de 23% (en grammes d’anticorps purifié par litre de résine et par jour) et le volume de tampon utilisé a été réduit de 25%. De plus, le couplage production/purification a permis de s’affranchir du stockage de volumes importants de filtrat (7,2L de filtrat par jour de production en perfusion). Enfin, une étude de coût de production, à l’échelle « laboratoire », a été réalisée afin de déterminer, en fonction de la productivité du clone et de la quantité d’anticorps à produire, la différence de rentabilité entre une production en batch ou en perfusion à différents CSPR. / Monoclonal antibodies are a biopharmaceuticals class of growing interest. Their production is widely studied to obtain higher yields and to reduce costs. This thesis describes the development of a complete continuous process, from the production of recombinant antibodies by mammalian cells until their purification. The objective is to connect cell culture in perfusion mode to a semi-continuous chromatographic purification. The development of the process was done in a bioreactor with a Chinese hamster ovary cell line (CHO-DP12) transformed to produce an anti-interleukin-8 antibody used as a cell model. After adaptation, the cells were cultured in batch mode in order to study the behavior of the cell line in controlled environment. Then, a 2L culture perfusion process with cell recycling was set up. The main challenge is to maintain a steady state with constant cell concentration and to determine the optimal cell-specific perfusion rate (CSPR). Several methods were tested and compared for the determination of this optimal CSPR. The perfusion process was maintained for 24 days at cell concentrations of 10, 20 and 40 million cells per mililiters. The antibody produced by different culture methods was compared (batch, fed-batch and perfusion). The N-glycosylations, the charge variants as well as the thermo-stability of the antibody were studied. The results show that the produced antibody have similar characteristics whatever the chosen production mode. For purification process, we performed a preliminary study to characterize the behavior of the supernatant on the chromatographic affinity resin MabSelect Sure LX. A semi-continuous process was simulated through BioSC® Predict software and then tested and optimized on the BioSC® chromatograph. It includes antibody purification but also cleaning and sanitizing steps. A first production/purification coupling test was successfully carried out for 32 h. It provides antibodies at a purity level similar to that of the conventional chromatography. Productivity was increased by 23% (in grams of purified antibody per liter of resin per day) and the volume of buffer used was reduced by 25%. In addition, production/purification coupling prevented storage of large volumes of supernatant (7,2L of supernatant per production day in perfusion mode). Finally, a cost-of-production study, at research scale, was carried out to determine, depending on the productivity of the clone and the antibodies amount, the difference of costs between batch or perfusion production according to different CSPRs.

Des hormones gonadotropiques sont utilisées pour la maîtrise de la reproduction dans le domaine vétérinaire. Ces hormones sont actuellement extraites de tissus ou de fluides animaux. L’entreprise CEVA Santé Animale a récemment fait le choix stratégique de produire ces hormones par voie recombinante. L’objectif de cette étude était d’obtenir une gonadotropine chorionique équine recombinante, reCG, pure et biologiquement active, à partir d’une lignée de cellules mammifères CHO. Les étapes de production, de purification et de caractérisation de l’hormone recombinante ont été développées. Les cellules CHO ont été cultivées en fiole d’Erlenmeyer dans différents milieux de culture. Le suivi de la croissance cellulaire et de la quantité d’hormone produite a permis de sélectionner deux milieux. Le procédé de production, avec ces deux milieux, a été optimisé en bioréacteur en contrôlant les paramètres de culture (température, pH). Les protéines produites dans le surnageant, de ces deux cultures, ont été nommées reCG 1 et reCG 2. Un procédé de purification en 3 étapes a été mis au point pour la reCG 1. Plusieurs résines et conditions chromatographiques ont été criblées en microplaques. Les résines multimodales utilisées ont permis d’éliminer des contaminants majeurs grâce à leur sélectivité. Les agrégats de la reCG ont été éliminés grâce à une résine anionique. Le procédé de purification global a été validé pour la reCG 1 et la reCG 2. Il a permis d’obtenir une pureté de 98 % avec un rendement de 80 %. L’activité biologique de la reCG 1 et la reCG 2, in vitro et in vivo, est comparable à celle de la protéine naturelle. L’activité biologique in vivo des reCG est cohérente avec l’étude réalisée sur les glycosylations des hormones et notamment avec leur degré de sialylation. / The gonadotrophic hormones are used for reproduction control in farming animals. Up to now, these hormones were extracted from animal fluids or tissues. The company CEVA Santé Animal has recently decided to produce recombinant versions of these hormones. The objective of this study was to obtain a pure and biologically active recombinant equine chorionic gonadotropin (reCG) after expression in CHO mammalian cells. The production, purification and characterization steps have been developed. CHO cells were grown in Erlenmeyer flasks with different culture media. Two media were selected based on their cell growth potency and of the amount of reCG produced. By using a bioreactor to control key parameters (temperature, pH), the production process was then optimized. The recombinant proteins that accumulated in the supernatant of the two conditions were called reCG 1 and reCG 2. A 3-steps purification process was then developed using reCG 1. Several resins and chromatographic conditions were screened in microplates. Multimodal resins were used to eliminate the main contaminants thanks to their selectivity. reCG aggregates were efficiently eliminated by a chromatographic step with an anionic resin. The overall purification process was finally validated for reCG 1 and reCG 2. Purity and yield were respectively, 98 % and 80 % for the two reCG. We verified that the in vitro and in vivo activities of reCG 1 and reCG 2 were comparable to those of the CG extracted from natural sources. The in vivo assays also confirmed previous studies showing that the degree of glycosylation of an hormone, and most notably their level of sialytation, is important for their biological activity.

O projeto de obtenção de huAcMos (Anticorpos Monoclonais Humanizados) tinha como escopo a humanização de anticorpos murinos com potencial terapêutico, inserção das sequências em vetores de expressão e transfecção em células CHO (do inglês, Chinese Hamster Ovary). A expressão do huAcMo Anti-CD18 resultou em baixos níveis da proteína recombinante e inciamos o processo de expressão de isoformas do huAcMo Anti-CD3. As células foram transfectadas com seqüências codificadoras do fragmento FvFc Anti-CD3 e clonadas pelo equipamento ClonePix FL. O fragmento foi caracterizado e demonstrou uma menor afinidade quando comparada com a molécula murina original. Ulizamos o sistema de recombinação homóloga (CHO Flp-In, Invitrogen) para expressão da molécula inteira do huAcMo Anti-CD3. Os clones foram caracterizados e demonstrou, assim como o fragmento FvFc, uma menor afinidade pelo alvo. As diferenças nas propriedades de ligação são freqüentemente encontradas após processos de humanização; dependendo da função efetora esta diminuição de afinidade não é negativa para a molécula. / The humanized antibodies (huMab) project intent to use murine antibodies with therapeutic potencial to obtain more human sequences with maintened specificity. The sequences were inserted in expression vectors and transfected in CHO (Chinese Hamster Ovary) cells. Anti-CD18 huMab expression results in low levels of recombinant protein and lead us to try the expression of Anti-CD3 isoforms. The cells were transfected for the expression of a FvFc antibody fragment and cloned using ClonePix FL equipment. The fragment characterization demonstrate a lower affinity when compared with the murine molecule. We use the homologous recombination system (CHO Flp-In) for the expression of the whole molecule of huMab Anti-CD3; like the FvFc fragment, the whole molecule demonstrate a lower affinity for the target. The differences in the affinity properties are frequently found after humanization process and depending on the expected efector functions is not negatively characterized.

This diploma thesis deals with study of the rate-dependence of the magnitude of a current through the heart channel that conducts slowly activating component of delayed rectifier outward current (IKs). This property is very important for the IKs channel function. When other repolarizing currents are insufficient, but also when the heart rate accelerates, especially during elevated sympathetic tone, IKs provides so-called repolarization reserve, which prevents excessive lengthening of cardiac action potential repolarization. The IKs channel structure is encoded by the KCNQ1 (pore-forming -subunit) and KCNE1 (modulatory -subunit) genes. Mutations in these genes disrupt the physiological function of the IKs channel and cause inherited arrhythmogenic syndromes, especially long QT syndrome (LQTS). Such mutations include the c.926C>T (p.T309I) mutation in the KCNQ1 gene, which results in LQTS type 1 in heterozygous carriers. The theoretical part of the thesis provides basic information about the IKs channel and the patch clamp technique, this knowledge is necessary for the practical part. The experimental part is focused on cultivation of the CHO cell line and its transient transfection for subsequent electrophysiological measurements by whole-cell patch clamp technique to study the dependence of the IKs magnitude on stimulation frequency, both in the wild type channels (i.e. without mutation) and in those with cotransfected wild type and T309I subunits.

Produktionen av rekombinanta biofarmaceutiska läkemedel, exempelvis monoklonala antikroppar, är en oumbärlig men ansträngande process. Under 2019 var sju av de tio mest sålda läkemedlen globalt baserade på rekombinant producerade monoklonala antikroppar. En betydande flaskhals i utvecklingen av stabila cellinjer är screening och selektion av högproducerande singelcellkloner. Tekniker som utspädningskloning (limiting dilution) och fluorescensaktiverad cellsortering (FACS) når idag medelmåttiga resultat som bäst, men saknar förmåga att både isolera produktiva singelcellkloner och hålla cellviabilitet på en acceptabel nivå. Samtidigt kan CellCelectorn™, ett helt automatiserat instrument utformat för att detektera, selektera och isolera singelcellkloner, screena celler för att kartlägga deras produktivitet. CellCelectorn™ är utrustad både med brightfield- och fluorescerande kameror och kan ranka samtliga cellkloner i en provplatta efter produktivitet för att sedan överföra de mest lovande klonerna till en destinationsplatta för vidare analyser och singelklonexpansion. Med avstamp i detta instrument var syftet med projektet att utveckla ett automatiserat arbetsflöde för screening och selektion av högproducerande singelcellkloner med hög genomströmning vid generering av stabila cellinjer. Inledande tester med redan utvecklade och produktiva cellinjer genomfördes för att undersöka CellCelectorns™ prestanda och för att upprätta och optimera sekundära parametrar relevanta för instrumentets kapacitet. Då dessa inledande tester var framgångsrika utfördes en polyklonal selektion i syfte att utveckla tre stabila cellinjer producerandes olika antikroppar. Dessa cellinjer skulle sedan användas för att undersöka CellCelectorns™ förmåga att isolera och överföra de mest lovande singelklonerna till en destinationsplatta. Dessa test kunde tyvärr inte genomföras, då kontaminering i de polyklonala poolerna hade uppstått, men de övergripande resultaten av detta projekt indikerar att CellCelectorn™ är kapabel till att screena för och ranka singelkloner efter deras produktivitet samt att selektera högproducerande klonkandidater under en enda arbetsvecka. Framtida tester är dock nödvändiga för att säkerställa CellCelectorns™ förmåga att isolera singelcellkloner med hög genomsnittlig cellviabilitet för att kunna genomföra singelklonexpansion. / The production of recombinant biopharmaceuticals, such as monoclonal antibodies (mAbs), from stable mammalian cell lines is an indispensable yet strenuous process. In 2019, seven of the top ten most sold drugs globally were based on monoclonal antibodies produced recombinantly. A prominent bottleneck in stable cell line development is the screening and selection of high target protein producing single clone candidates. Today, techniques such as limiting dilution and Fluorescence Activated Cell Sorting (FACS) receive moderate success at best at isolating single clones while keeping cell viability high. Simultaneously, the CellCelector™ is a fully automated instrument designed for the detection, selection, and isolation of single cell clones. Containing both a brightfield and fluorescence-detecting camera, the CellCelector™ can screen cells to measure their productivity and rank them accordingly, meaning high target protein producing clones can be selected and transferred to a destination plate for single clone expansion. Thus, this project aimed at developing an automated high-throughput workflow using the CellCelector™ to streamline the screening and selection steps of stable mammalian cell line generation. Several tests with stable proof-of-concept cells were performed to evaluate the performance of the CellCelector™ and to establish favorable secondary parameter settings. As initial proof-of-concept tests showed promise, a polyclonal selection to obtain three stable Human Embryonic Kidney (HEK) cultures expressing different antibodies was carried out in order to test the CellCelector™ proficiency in clone selection and picking. Unfortunately, no clone picking or single clone expansion could be executed due to bacterial contamination in the cell cultures. Nevertheless, the overall results of this project indicate high potential of the CellCelector™ to detect and identify promising stable clone candidates for single clone expansion over the course of a single work week. Future tests are however required to solidify CellCelector™ ability to isolate monoclonal clones while preserving cell viability for single clone expansion.